Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Akagi, Yuina, Yamashita, Yusuke, Kosako, Hideki, Furuya, Yoshiaki, Hosoi, Hiroki, Mushino, Toshiki, Murata, Shogo, Nishikawa, Akinori, Tamura, Shinobu, Nakao, Taisei, Sonoki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435694/
https://www.ncbi.nlm.nih.gov/pubmed/37601888
http://dx.doi.org/10.1002/jha2.732
Descripción
Sumario:Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73‐year‐old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.

Ejemplares similares